Claims
- 1. A 2,4-oxazolidinedione compound of the formula: ##STR99## wherein R is oxazolyl, thiazolyl or triazolyl which groups are unsubstituted or are substituted by 1 to 3 substituents selected from the group consisting of
- (1) C.sub.1 -C.sub.3 alkyl,
- (2) phenyl,
- (3) naphthyl,
- (4) furyl, and
- (5) thienyl,
- A is bivalent straight or branched hydrocarbon having 1 to 4 carbon atoms,
- R.sup.1 and R.sup.2 are each hydrogen or alkyl of 1 to 4 carbon atoms, and L and M are each hydrogen or are combined with each other to form a bond,
- or a pharmaceutically acceptable salt thereof.
- 2. A compound or pharmaceutically acceptable salt according to claim 1 wherein R is oxazolyl or thiazolyl, said groups being unsubstituted or substituted as defined in claim 1.
- 3. A compound or pharmaceutically acceptable salt according to claim 1 of the formula ##STR100##
- 4. A compound or pharmaceutically acceptable salt according to claim 3 wherein L and M are each hydrogen and R.sup.1 and R.sup.2 are each hydrogen.
- 5. A compound or pharmaceutically acceptable salt according to claim 4 wherein A is --CH.sub.2 CH.sub.2 --.
- 6. A compound or pharmaceutically acceptable salt according to claim 4 wherein R is oxazolyl.
- 7. A compound or pharmaceutically acceptable salt according to claim 1 of the formula ##STR101##
- 8. A compound as claimed in claim 1, wherein the compound is 5-[3-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]propyl]-2,4-oxazolidinedione or a pharmaceutically acceptable salt thereof.
- 9. A compound as claimed in claim 1, wherein the compound is 5-[3-[4-(5-methyl-4-phenyl-2-thiazolylmethoxy)phenyl]propyl]-2,4-oxazolidinedione or a pharmaceutically acceptable salt thereof.
- 10. A compound as claimed in claim 1, wherein the compound is 5-[5-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]pentyl]-2,4-oxazolidinedione or a pharmaceutically acceptable salt thereof.
- 11. A pharmaceutical composition for the treatment of diabetes or hyperlipidemia which comprises an effective amount of a compound or pharmaceutically acceptable salt thereof as defined in claim 1 and a pharmaceutically acceptable carrier therefor.
- 12. A pharmaceutical composition according to claim 11 wherein the compound is of the formula ##STR102##
- 13. A method for the treatment of a mammal suffering from diabetes or hyperlipidemia which comprises administering to such mammal an effective amount of a compound or pharmaceutically acceptable salt as defined in claim 1.
Priority Claims (2)
Number |
Date |
Country |
Kind |
5-038236 |
Feb 1993 |
JPX |
|
5-197304 |
Aug 1993 |
JPX |
|
Parent Case Info
This application is a continuation of now abandoned application Ser. No. 08/201,021, filed Feb. 24, 1994.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4430337 |
Holland |
Feb 1984 |
|
5037842 |
Goldstein |
Aug 1991 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
0 428 312 |
May 1991 |
EPX |
WO9202520 |
Feb 1992 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Sohda et al. Chem. Pharm. Bull 30(10) 3580-3600 1982. |
Clark et al. CA 115:136086 1991. |
Dow et al. CA 114:228799 1991. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
201021 |
Feb 1994 |
|